TheRas, Inc. (d/b/a BBOT)

Contributing Author

Recent Articles by TheRas, Inc. (d/b/a BBOT)

May-12	BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress BBOT GlobeNewswire
May-12	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBOT GlobeNewswire
Apr-22	BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 BBOT -6.24% GlobeNewswire
Apr-22	BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman BBOT -6.24% GlobeNewswire
Apr-21	BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 BBOT GlobeNewswire
Apr-20	BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma BBOT GlobeNewswire
Apr-13	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBOT +6.55% GlobeNewswire
Mar-18	BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 BBOT -6.33% GlobeNewswire
Mar-06	BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor BBOT +5.36% GlobeNewswire
Mar-05	BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress BBOT GlobeNewswire
Feb-12	BBOT to Participate in Upcoming Investor Healthcare Conferences BBOT -5.15% GlobeNewswire
Feb-11	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBOT +11.07% GlobeNewswire
Jan-13	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBOT -9.16% GlobeNewswire
Jan-07	BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs BBOT GlobeNewswire
Dec-16	BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference BBOT GlobeNewswire
Dec-11	BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBOT GlobeNewswire
Dec-10	BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS) BBOT GlobeNewswire
Nov-18	BBOT to Participate in Upcoming December Investor Healthcare Conferences BBOT -5.93% BBOT GlobeNewswire
Nov-12	BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress BBOT GlobeNewswire
Nov-03	BBOT to Participate in the Jefferies Global Healthcare Conference in London BBOT GlobeNewswire
Oct-30	BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) BBOT GlobeNewswire
Oct-25	Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia BBOT GlobeNewswire
Oct-23	BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics BBOT GlobeNewswire
Oct-13	BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics BBOT GlobeNewswire
Aug-20	BBOT to Participate in Upcoming September Investor Healthcare Conferences BBOT -5.59% GlobeNewswire

TheRas, Inc. (d/b/a BBOT)

Recent Articles by TheRas, Inc. (d/b/a BBOT)

Upgrade your Finviz experience